1. Technology overview
CorFlow Therapeutics AG is a Swiss medtech company at Neuhofstrasse 5A, 6340 Baar (VAT CHE 320.873.257). It develops a device to diagnose microvascular obstruction (MVO) during percutaneous coronary intervention and to act as a treatment platform in the cath lab.
The Controlled Flow Infusion (CoFI) System detects MVO, compared with cardiac MRI as gold standard in STEMI patients, and returns microvascular diagnostic information within minutes. It works through the existing guide catheter and wire access and can deliver pharmaceutical or other agents directly into the vasculature by controlled infusion. The system is investigational and not approved in the United States.
2. Highlighted features & specifications
- MVO detection: Diagnoses microvascular obstruction during PCI.
- Fast results: Delivers diagnostic information within minutes.
- Workflow fit: Uses the existing guide catheter and wire access.
- Controlled infusion: Delivers pharmaceutical or other agents into the vasculature.
- Platform use: Designed as a diagnostic and treatment platform for the cath lab.
3. Potential application
Primary PCI for STEMI patients in tertiary cardiology hospitals in Vietnam. Clinical research collaborations on microvascular injury. Cath-lab trials of targeted drug delivery.
4. Benefits
Microvascular diagnostic information within minutes during the PCI procedure. Uses the existing guide catheter and wire access, so it fits the PCI workflow. Controlled infusion can deliver therapeutic agents directly to the affected vasculature. Addresses a complication of heart attack for which the company cites MOCA clinical trials.
5. Market trends & opportunities
Microvascular obstruction after heart attack remains an unaddressed complication, and cath-lab devices that combine diagnosis with therapy are an active development area. Interventional cardiology centers in Vietnam performing primary PCI would be potential adopters after regulatory approval.
6. Other information
Swiss company in Baar (CorFlow Therapeutics AG). Per Startupticker (7 May 2026): Phase 1 of the MOCA II FDA pivotal trial enrolled 19 STEMI patients at eight sites; Phase 2 started at Cardiocentro Ticino; the REVITALISE trial was approved in the UK. The website states the CoFI System is investigational only. Founding year not stated.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE









































